AVEO Oncology (AVEO) Tops Q3 EPS by 6c; Reports Cash and Cash Equivalents of $94.0M

AVEO Oncology (NASDAQ: AVEO) reported Q3 EPS of ($0.30), $0.06 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $13.8 million.

For earnings history and earnings-related data on AVEO Oncology (AVEO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Optimum Communications gets NYSE non-compliance notice over stock price
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M